Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: resolution with rituximab.
Bone marrow necrosis is a rare cause of bone marrow failure. Malignancy is the most frequent cause of bone marrow necrosis. Among malignancies, non-Hodgkin lymphoma (NHL) accounts for 10% of cases of bone marrow necrosis. Virtually all reported cases of NHL-associated bone marrow necrosis have developed in immunocompetent hosts. We report on a case of bone marrow necrosis complicating post-transplant lymphoproliferative disorder (PTLD) and resolving after rituximab monotherapy. This case report provides the first evidence of (i) bone marrow necrosis as a complication of PTLD; (ii) rapid resolution of NHL-associated bone marrow necrosis after rituximab treatment.
Rossi
Davide
D
Division of Hematology, Department of Clinical and Experimental Medicine & IRCAD, Amedeo Avogadro University of Eastern Piedmont and Ospedale Maggiore della Carità, Via Solaroli 17, 28100 Novara, Italy. rossidav@med.unipmn.it
Ramponi
Antonio
A
Franceschetti
Silvia
S
Stratta
Piero
P
Gaidano
Gianluca
G
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001853:Bone Marrow / Q000473:pathology*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009336:Necrosis; D049268:Positron-Emission Tomography; D000069283:Rituximab; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab